257 related articles for article (PubMed ID: 27884016)
1. Expression profiling of budding cells in colorectal cancer reveals an EMT-like phenotype and molecular subtype switching.
De Smedt L; Palmans S; Andel D; Govaere O; Boeckx B; Smeets D; Galle E; Wouters J; Barras D; Suffiotti M; Dekervel J; Tousseyn T; De Hertogh G; Prenen H; Tejpar S; Lambrechts D; Sagaert X
Br J Cancer; 2017 Jan; 116(1):58-65. PubMed ID: 27884016
[TBL] [Abstract][Full Text] [Related]
2. Tumour budding is associated with the mesenchymal colon cancer subtype and RAS/RAF mutations: a study of 1320 colorectal cancers with Consensus Molecular Subgroup (CMS) data.
Trinh A; Lädrach C; Dawson HE; Ten Hoorn S; Kuppen PJK; Reimers MS; Koopman M; Punt CJA; Lugli A; Vermeulen L; Zlobec I
Br J Cancer; 2018 Nov; 119(10):1244-1251. PubMed ID: 30385823
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinase receptor B (TrkB) expression in colorectal cancers highlights anoikis resistance as a survival mechanism of tumour budding cells.
Dawson H; Grundmann S; Koelzer VH; Galván JA; Kirsch R; Karamitopoulou E; Lugli A; Inderbitzin D; Zlobec I
Histopathology; 2015 Apr; 66(5):715-25. PubMed ID: 25382057
[TBL] [Abstract][Full Text] [Related]
4. Epithelial-mesenchymal transition (EMT) protein expression in a cohort of stage II colorectal cancer patients with characterized tumor budding and mismatch repair protein status.
Kevans D; Wang LM; Sheahan K; Hyland J; O'Donoghue D; Mulcahy H; O'Sullivan J
Int J Surg Pathol; 2011 Dec; 19(6):751-60. PubMed ID: 21791486
[TBL] [Abstract][Full Text] [Related]
5. Combined epithelial marker analysis of tumour budding in stage II colorectal cancer.
Slik K; Blom S; Turkki R; Välimäki K; Kurki S; Mustonen H; Haglund C; Carpén O; Kallioniemi O; Korkeila E; Sundström J; Pellinen T
J Pathol Clin Res; 2019 Jan; 5(1):63-78. PubMed ID: 30358171
[TBL] [Abstract][Full Text] [Related]
6. TWIST1 and TWIST2 promoter methylation and protein expression in tumor stroma influence the epithelial-mesenchymal transition-like tumor budding phenotype in colorectal cancer.
Galván JA; Helbling M; Koelzer VH; Tschan MP; Berger MD; Hädrich M; Schnüriger B; Karamitopoulou E; Dawson H; Inderbitzin D; Lugli A; Zlobec I
Oncotarget; 2015 Jan; 6(2):874-85. PubMed ID: 25528769
[TBL] [Abstract][Full Text] [Related]
7. High-throughput mRNA and miRNA profiling of epithelial-mesenchymal transition in MDCK cells.
Shukla P; Vogl C; Wallner B; Rigler D; Müller M; Macho-Maschler S
BMC Genomics; 2015 Nov; 16():944. PubMed ID: 26572553
[TBL] [Abstract][Full Text] [Related]
8. Predictive power of tumour budding for lymph node metastasis in colorectal carcinomas: A retrospective study.
Deb B; Jacob SE
Indian J Med Res; 2019 Dec; 150(6):635-639. PubMed ID: 32048628
[TBL] [Abstract][Full Text] [Related]
9. The impact of CpG island methylator phenotype and microsatellite instability on tumour budding in colorectal cancer.
Zlobec I; Bihl MP; Foerster A; Rufle A; Lugli A
Histopathology; 2012 Nov; 61(5):777-87. PubMed ID: 22803799
[TBL] [Abstract][Full Text] [Related]
10. Epithelial-to-mesenchymal transition signature assessment in colorectal cancer quantifies tumour stromal content rather than true transition.
McCorry AM; Loughrey MB; Longley DB; Lawler M; Dunne PD
J Pathol; 2018 Dec; 246(4):422-426. PubMed ID: 30105762
[TBL] [Abstract][Full Text] [Related]
11. Identification of gene signatures for invasive colorectal tumor cells.
Wiese AH; Auer J; Lassmann S; Nährig J; Rosenberg R; Höfler H; Rüger R; Werner M
Cancer Detect Prev; 2007; 31(4):282-95. PubMed ID: 17936523
[TBL] [Abstract][Full Text] [Related]
12. Tumour budding in colorectal cancer: what do we know and what can we do?
De Smedt L; Palmans S; Sagaert X
Virchows Arch; 2016 Apr; 468(4):397-408. PubMed ID: 26613731
[TBL] [Abstract][Full Text] [Related]
13. Tumour budding at invasive margins and outcome in colorectal cancer.
Kanazawa H; Mitomi H; Nishiyama Y; Kishimoto I; Fukui N; Nakamura T; Watanabe M
Colorectal Dis; 2008 Jan; 10(1):41-7. PubMed ID: 18078460
[TBL] [Abstract][Full Text] [Related]
14. A partial epithelial-mesenchymal transition signature for highly aggressive colorectal cancer cells that survive under nutrient restriction.
Pastorino GA; Sheraj I; Huebner K; Ferrero G; Kunze P; Hartmann A; Hampel C; Husnugil HH; Maiuthed A; Gebhart F; Schlattmann F; Gulec Taskiran AE; Oral G; Palmisano R; Pardini B; Naccarati A; Erlenbach-Wuensch K; Banerjee S; Schneider-Stock R
J Pathol; 2024 Mar; 262(3):347-361. PubMed ID: 38235615
[TBL] [Abstract][Full Text] [Related]
15. Oncogene FOXK1 enhances invasion of colorectal carcinoma by inducing epithelial-mesenchymal transition.
Wu Y; Peng Y; Wu M; Zhang W; Zhang M; Xie R; Zhang P; Bai Y; Zhao J; Li A; Nan Q; Chen Y; Ren Y; Liu S; Wang J
Oncotarget; 2016 Aug; 7(32):51150-51162. PubMed ID: 27223064
[TBL] [Abstract][Full Text] [Related]
16. A Composite Gene Expression Signature Optimizes Prediction of Colorectal Cancer Metastasis and Outcome.
Schell MJ; Yang M; Missiaglia E; Delorenzi M; Soneson C; Yue B; Nebozhyn MV; Loboda A; Bloom G; Yeatman TJ
Clin Cancer Res; 2016 Feb; 22(3):734-45. PubMed ID: 26446941
[TBL] [Abstract][Full Text] [Related]
17. Presence of Twist1-positive neoplastic cells in the stroma of chromosome-unstable colorectal tumors.
Celesti G; Di Caro G; Bianchi P; Grizzi F; Basso G; Marchesi F; Doni A; Marra G; Roncalli M; Mantovani A; Malesci A; Laghi L
Gastroenterology; 2013 Sep; 145(3):647-57.e15. PubMed ID: 23684708
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical study of the epithelial-mesenchymal transition phenotype in cancer of unknown primary: incidence, correlations and prognostic utility.
Stoyianni A; Goussia A; Pentheroudakis G; Siozopoulou V; Ioachim E; Krikelis D; Golfinopoulos V; Cervantes A; Bobos M; Fotsis T; Bellou S; Fountzilas G; Malamou-Mitsi V; Pavlidis N
Anticancer Res; 2012 Apr; 32(4):1273-81. PubMed ID: 22493359
[TBL] [Abstract][Full Text] [Related]
19. Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated Snail/E-cadherin expression.
Ji Q; Liu X; Han Z; Zhou L; Sui H; Yan L; Jiang H; Ren J; Cai J; Li Q
BMC Cancer; 2015 Mar; 15():97. PubMed ID: 25884904
[TBL] [Abstract][Full Text] [Related]
20. Epithelial mesenchymal transition in colorectal cancer: Seminal role in promoting disease progression and resistance to neoadjuvant therapy.
Bhangu A; Wood G; Mirnezami A; Darzi A; Tekkis P; Goldin R
Surg Oncol; 2012 Dec; 21(4):316-23. PubMed ID: 22981546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
